MedDataX Logo

PMS Assessing the Long-term Efficacy and Safety of Nevirapine Therapy (Combined With Other ARV Drugs) in HIV-1 Positive Patients in Daily Clinical Practice.

NCT ID: NCT00736502

Last Updated: 2014-03-07

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

280 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this trial is to evaluate the safety and virological and immunological efficacy of Viramune® on a background of different antiretroviral drug combinations.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long-term Study in Patients Under Anti-retroviral Combination Therapy Switching to Viramune®

NCT02191293

HIV Infections
COMPLETED

Observational Study in Patients With HIV Infection Type 1 After Switching to a Viramune®-Containing Therapy Regimen

NCT02191332

HIV Infections
COMPLETED

Impact of Switching to NNRTI-based Therapy on the Quality of Life of HIV-infected Patients With Virological Suppression

NCT02191202

HIV Infections
COMPLETED

Observational Study With Antiretroviral Treated Patients Switching to Nevirapine Plus Two Nucleoside Reverse Transcriptase Inhibitor (NRTI) Regimens

NCT02191319

HIV Infections
COMPLETED

Non-interventional Observational Study With Viramune® in HIV to Evaluate Gender Specific Data

NCT01134939

HIV Infections
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients HIV-1 positive

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Inclusion criteria:

The inclusion criteria follow the same criteria which are describe in the newest SPC.

Exclusion criteria:

The exclusion criteria follow the same criteria which are describe in the newest SPC.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Boehringer Ingelheim Investigational Site 1

Graz, , Austria

Site Status

Boehringer Ingelheim Investigational Site 2

Linz, , Austria

Site Status

Boehringer Ingelheim Investigational Site 3

Salzburg, , Austria

Site Status

Boehringer Ingelheim Investigational Site 4

Vienna, , Austria

Site Status

Boehringer Ingelheim Investigational Site 5

Vienna, , Austria

Site Status

Boehringer Ingelheim Investigational Site 6

Vienna, , Austria

Site Status

Boehringer Ingelheim Investigational Site 7

Wels, , Austria

Site Status

Boehringer Ingelheim Investigational Site 8

Bialystok, , Poland

Site Status

Boehringer Ingelheim Investigational Site 9

Bydgoszcz, , Poland

Site Status

Boehringer Ingelheim Investigational Site 10

Chorzów, , Poland

Site Status

Boehringer Ingelheim Investigational Site 11

Gdansk, , Poland

Site Status

Boehringer Ingelheim Investigational Site 12

Krakow, , Poland

Site Status

Boehringer Ingelheim Investigational Site 13

Lódz, , Poland

Site Status

Boehringer Ingelheim Investigational Site 14

Poznan, , Poland

Site Status

Boehringer Ingelheim Investigational Site 15

Szczecin, , Poland

Site Status

Boehringer Ingelheim Investigational Site 16

Warsaw, , Poland

Site Status

Boehringer Ingelheim Investigational Site 17

Wroclaw, , Poland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria Poland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1100.1527

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Genotype Based Personalized Prescription of Nevirapine
NCT00986063 COMPLETED PHASE4
Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)
NCT00615563 COMPLETED
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
NCT07053384 RECRUITING PHASE1
Efficacy Safety Study Comparing 2 Doses of NVP After Initiating Rifampin-containing TB Therapy
NCT00476853 COMPLETED PHASE2
Registry to Assess Long-term Outcome in HIV Subjects Who Participated in Phase 2 and 3 Clinical Trials Involving Vicriviroc (Study P04999)
NCT00705419 COMPLETED
Effectiveness of Antiretroviral Therapy During Acute HIV Infection
NCT00705926 COMPLETED PHASE1
Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens
NCT00627055 COMPLETED PHASE4
A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions
NCT00144248 COMPLETED PHASE4
Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia Suppression
NCT01034917 COMPLETED PHASE3
Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting
NCT01772940 COMPLETED PHASE4
Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
NCT01968551 COMPLETED PHASE3
Effect of Dolutegravir Compared With Darunavir/Cobicistat on the Severity of Neuropsychiatric Effects al 12 Weeks in Antirretroviral Treatment-Naive Adults.
NCT06787976 NOT_YET_RECRUITING PHASE4
Quality of Life and Changes in Metabolism of Lipids and Glucose After Switching to a Nevirapine-based Regimen in HIV+ Patients
NCT00274001 COMPLETED PHASE4
Accurate Staging of Immuno-virological Dynamics During Acute HIV Infection
NCT03449706 RECRUITING
Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTI Mutation K103N
NCT05349838 COMPLETED PHASE3
GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults
NCT00257621 COMPLETED PHASE2
MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002)
NCT03552536 COMPLETED PHASE1
Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix
NCT07182838 ACTIVE_NOT_RECRUITING EARLY_PHASE1
CD4 Cell Recovery in HIV-1 Patients Comparing 2 Treatment Regimes
NCT00966160 COMPLETED PHASE3
A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
NCT01266902 COMPLETED PHASE3
Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl
NCT00532168 COMPLETED PHASE4
An Evaluation of the Development of Nevirapine Induced Mutations in HIV Patients Initiating or Discontinuing Combination Antiretroviral Therapy
NCT00193947 TERMINATED
Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection
NCT00062660 APPROVED_FOR_MARKETING
A 72-week Randomized Clinical Trial Comparing the Safety and Efficacy of Three Initial Antiretroviral Regimens -GPO-VIR S (d4T/3TC/NVP) for 24 Weeks Followed by GPO-VIR Z (AZT/3TC/NVP) vs GPO-VIR Z vs TDF/FTC/NVP
NCT00669487 COMPLETED PHASE3
Accelerated ART Initiation for PWHIV Who Are Out of Care
NCT06374758 RECRUITING PHASE4